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Abstract: Human Amylin, or islet amyloid polypeptide (hIAPP), is a small hormone secreted
by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and
it constitutes a pathological hallmark of type II diabetes mellitus. In type II diabetes patients, amylin
is abnormally increased, self-assembled into amyloid aggregates, and ultimately contributes to the
apoptotic death of β-cells by mechanisms that are not completely understood. We have screened a
library of approved drugs in order to identify inhibitors of amylin aggregation that could be used as
tools to investigate the role of amylin aggregation in type II diabetes or as therapeutics in order to
reduce β-cell damage. Interestingly, three of the compounds analyzed—benzbromarone, quercetin,
and folic acid—are able to slow down amylin fiber formation according to Thioflavin T binding,
turbidimetry, and Transmission Electron Microscopy assays. In addition to the in vitro assays, we have
tested the effect of these compounds in an amyloid toxicity cell culture model and we have found
that one of them, quercetin, has the ability to partly protect cultured pancreatic insulinoma cells from
the cytotoxic effect of amylin. Our data suggests that quercetin can contribute to reduce oxidative
damage in pancreatic insulinoma β cells by modulating the aggregation propensity of amylin.
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1. Introduction
Type II diabetes is a metabolic disorder of increasing prevalence (10% in USA and 5%
worldwide) [1,2]. It is characterized by resistance to and/or low levels of insulin production linked to
the damage of pancreatic β cells [3,4]. This damage has been associated with the presence of amyloid
aggregates that become more abundant as the disease progresses [5,6]. The major component of β cells
amyloid deposits is a 37 amino acid peptide, termed human islet amyloid polypeptide (hIAPP) or
amylin, a hormone secreted along with insulin in the pancreas [7]. Amylin contributes to the regulation
of blood glucose levels by controlling the rate at which glucose enters the blood stream. Amyloid fibers
of IAPP have been described in humans, other primates, and cats [8]. Rodent IAPP, only differing from
hIAPP in six residues, does not form amyloids [9]. It is believed that hIAPP amyloidogenicity may be
related to a protein segment comprising amino acids 20–39 [10].
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Proteins can form different types of insoluble aggregates, either amorphous or fibrillar. Amylin
forms stacked cross-β-sheet fibers [11–14]. Several studies have pointed out that in amyloid diseases
the main cytotoxic effect is associated with the small early forming oligomers of misfolded proteins
rather than with the larger mature amyloid fibers [15–20]. Thus, inhibiting the formation of cytotoxic
oligomers early in the aggregation reaction might constitute a promising strategy to minimize cellular
damage in type II diabetes and in other amyloidogenic diseases [21], such as Alzheimer’s or Parkinson’s
disease, where aggregates of the amyloidβ peptide, Tau, orα-synuclein seem to play major roles [22,23].
Indeed, the inhibition of amyloid β peptide aggregation and Tau protein by small chemical compounds
has already reached clinical trials [24–27].
We have previously shown the feasibility of identifying bioactive compounds by screening large
libraries of chemicals [28–32]. Indeed, this is a very effective approach to rapidly find leads for
further improvement. Here we have searched for inhibitors of amylin aggregation using an amylin
fragment comprising amino acids 8–37, which includes all known amylin amyloid determinants [33]
and is known to induce cytotoxicity in pancreatic β-cells [34]. We have found three well-known
compounds—folic acid, quercetin, and benzbromarone—that inhibit amylin aggregation in vitro and
we have tested their effects on amylin treated pancreatic rat insulinoma β-cells.
2. Results and Discussion
2.1. Identification of Inhibitor Candidates
To identify inhibitors of amylin (8–37) aggregation, a high-throughput (HTS) assay based on the
increase in fluorescence associated to Thioflavin T (ThT) binding to amyloid fibrils was used [35].
Typical of an amyloidogenic peptide, Amylin (8–37) aggregation kinetics in the presence of ThT
follows a sigmoidal curve that reflects a nucleation-dependent growth mechanism, showing an initial
nucleation step followed by an elongation phase ending in a stationary phase (Figure 1). The Prestwick
library of 1220 compounds was first screened for inhibitors of aggregation including mixtures of five
different chemicals in each well. Then, compounds present in positive wells where the aggregation
of amylin (8–37) was inhibited were subsequently evaluated individually using otherwise identical
assay conditions. In this way, apparent inhibitory compounds were identified. Some of them turned
out to be true inhibitors and some were false positives that could be discarded with further analysis
(see below). Figure 1 shows the effects on the aggregation kinetics of the three chemical compounds
that were finally selected among the inhibitory candidates initially identified using the ThT assay.
When any of those compounds were present in the solution the increase in ThT fluorescence observed
was lower than that corresponding to a solution of peptide and ThT in the absence of the compound.
Detecting active compounds using fluorescence-based assays is prone to produce false positives,
especially among compounds absorbing the light emitted by the fluorescence probe used, because
such compounds lower the emission intensity even if they do not inhibit aggregation. In order to
distinguish between true inhibitors and false positives, turbidity and transmission electron microscopy
(TEM) analyses were performed.
2.2. Identification of True Inhibitors by Turbidity and Transmission Electron Microscopy (TEM) Analyses
A simple turbidimetric method was used to find out which of the compounds initially identified
in the ThT fluorescence assay were true aggregation inhibitors and which ones were false positives.
Aggregation of amylin (8–37) gives rise to high molecular weight aggregates that scatter light and
increase the turbidity of the solution, which can be detected by measuring the increase in absorbance
at 360 nm. For this assay, amylin (8–37) was incubated in the presence of each candidate compound
for 5.5 h, and the absorbance at 360 nm was measured every 30 min. The kinetics observed for the
aggregation of amylin controls in the absence of an inhibitor are compared to those observed when true
inhibitors were present (Figure 2). Three compounds completely avoided the building of turbidity in
the amylin solution and were considered to be aggregation inhibitors. This was confirmed using TEM
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by studying the influence of the inhibitors in the formation of amylin fibers. Amylin self-assembles
into typical long, unbranched fibrils as well as fibril bundles and twisted ribbons with various lengths
(up to 2 mm) (Figure 3a). Two of the inhibitors significantly lowered the amount of fibers formed
(Figure 3c,d). In the presence of compound 3 fibers are still detectable, but they differ in morphology
from those formed in its absence, indicating that the compound also impacts the fibrillation process
(Figure 3e).
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Figure 1. Inhibition of amylin (8–37) aggregation by benzbromarone, quercetin, and folic acid, 
followed by an increase in Thioflavin T (ThT) emission fluorescence at 482 nm. Black dots: positive 
aggregation control, only amylin; white dots: negative aggregation control (no amylin); Red,  
green, and cyan dots: aggregation of amylin in presence of benzbromarone, quercetin, and folic  
acid, respectively. 
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Figure 2. Kinetic aggregation assays of amylin (8–37) in the presence of benzbromarone, quercetin, 
and folic acid, followed by solution turbidity. Turbidity was measured as absorbance at 360 nm. Black 
dots: positive aggregation control (only amylin); white dots: negative aggregation control (no amylin); 
Red, green, and cyan dots: aggregation of amylin with the addition of benzbromarone, quercetin, and 
folic acid, respectively. 
The influence of Congo red and methylene blue in amylin fibril formation was also tested, as 
they have been described to protect against amylin cytotoxicity. When those compounds were first 
shown not to impair amylin aggregation [36,37], it was hypothesized that either their binding to the 
fibrils blocked their toxic effect or that the compounds inhibited the accumulation of toxic oligomeric 
species by promoting fibrillation. We have incubated amylin in the presence of Congo red or 
methylene blue in the same conditions used for our three inhibitory compounds and observed that 
they reduce amylin solution light scattering (Figure S1a) and, in agreement with previously described 
observations [36,37], well-structured amylin fibrils are clearly observed in the presence of either 
molecule (Figure S1b). 
0 1 2 3 4 5
0
5
10
15
20
25
E
m
is
si
on
 fl
uo
re
sc
en
ce
 (a
.u
.)
Time (h)
    amylin
  - amylin
 + Benzbromarone
 + Quercetin
 + Folic acid
Figure 1. Inhibition of amylin (8–37) aggregation by benzbromarone, quercetin, and folic acid, followed
by an increase in Thioflavi (ThT) emission fluorescence at 482 nm. Black dots: positive aggregation
control, only amylin; white dots: negative aggregation control (no amylin); Red, green, nd cyan dots:
aggregation of amylin in presence of benzbromarone, quercetin, a d folic cid, respectively.
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Figure 2. Kinetic aggregation assays of amylin (8–37) in the presence of benzbromarone, quercetin, and
folic acid, followed by solution turbidity. Turbidity was measured as absorbance at 360 nm. Black dots:
positive aggregation control (only amylin); white dots: negative aggregation control (no amylin); Red,
green, and cyan dots: aggregation of amylin with the addition of benzbromarone, quercetin, and folic
acid, respectively.
The influence of Congo red and methylene blue in amylin fibril formation was also tested, as they
have been described to protect against amylin cytotoxicity. When those compounds were first shown
not to impair amylin aggregation [36,37], it was hypothesized that either their binding to the fibrils
blocked their toxic effect or that the compounds inhibited the accumulation of toxic oligomeric species
by promoting fibrillation. We have incubated amylin in the presence of Congo red or methylene blue
in the same conditions used for our three inhibitory compounds and observed that they reduce amylin
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solution light scattering (Figure S1a) and, in agreement with previously described observations [36,37],
well-structured amylin fibrils are clearly observed in the presence of either molecule (Figure S1b).Int. J. Mol. Sci. 2016, 17, 964 4 of 11 
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Figure 3. Amylin aggregation inhibition visualized using transmission electron microscopy (TEM). 
Amylin (8–37) at 50 µM was incubated in the presence or absence of the compounds (at 100 µM), 
fibers were negatively stained and imaged using TEM. Positive control (amylin alone): panel (a); 
negative control (no amylin): panel (b); amylin in presence of benzbromarone, quercetin, and folic 
acid: panels (c, d, or e), respectively. The length of the scale bars is 0.2 µm. Compounds strongly 
inhibit amylin amyloid fibril formation. 
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Figure 3. Amylin aggregation inhibition visualized using transmission electron microscopy (TEM).
Amylin (8–37) at 50 µM was incubated in the presence or absence of the compounds (at 100 µM), fibers
were negatively stained and imaged using TEM. Positive control (amylin alone): panel (a); negative
control (no amylin): panel (b); amylin in presence of benzbromarone, quercetin, and folic acid: panels
(c, d, or e), respectively. The length of the scale bars is 0.2 µm. Compounds strongly inhibit amylin
amyloid fibril formation.
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2.3. Chemical Nature and Cellular Toxicity of the Three Inhibitors
The chemical structures of the three inhibitors are shown in Table 1. They are heterocyclic
compounds exhibiting no obvious chemical relationship: benzbromarone (molecular mass
(MM) = 424.1 and logP = 6.0), quercetin dihydrate (MM = 338.27 and logP = 1.5), and folic acid
(MM = 441.4 and logP = ´0.99). Folic acid contains one asymmetric center while benzbromarone and
quercetin are not chiral.
Table 1. Common names, systematic names, and chemical structures of three inhibitors of amylin
(8–37) aggregation.
Aggregation Inhibitors Structure
Benzbromarone:
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran;
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone
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(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone 
Quercetin dihydrate:  
3,3′,4′,5,7-pentahydroxyflavone dihydrate;  
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate 
Folic acid:  
pteroyl-L-glutamic acid 
pteroyl-L-glutamate 
The toxicity of the three inhibitors at different concentrations ranging from 10 nM to 200 µM was 
tested on HeLa cells using the Cell Proliferation Kit II (Roche, Basel, Switzerland), which detects cell 
dehydrogenase activity, by transformation of XTT (a tetrazolium salt) into a soluble colored formazan 
that can be quantified by absorbance. This absorbance is proportional to the number of viable cells. 
Toxicity curves (Figure S2) were fitted to a dose response equation to calculate half inhibitory 
concentrations (IC50). The most toxic inhibitor was benzbromarone, (IC50 = 43 ± 7 µM), then quercetin 
(110 ± 33 µM), although both of them were toxic only at relatively high concentrations. The toxicity 
of folic acid was very low (>200 µM) and could not be determined since it was above the tested range. 
These results showed that benzbromarone, quercetin, and folic acid display no significant toxicity 
towards HeLa cells at the medium-low concentration range tested. We then decided to keep a 
concentration of 10 µM for the three compounds during the following cytotoxicity protection 
experiments on cultured cells. 
2.4. Partial Inhibitory Effect of Quercetin on the Cytotoxicity Induced by Amylin (8–37) in Rat Insulinoma 
Pancreatic (RIN-m5F) Cells 
Rat insulinoma pancreatic cells (RIN-m5F) were used to evaluate whether any of the aggregation 
inhibitors could protect them against the cytotoxic effect exerted by amylin. The dyes Congo red and 
methylene blue, which have been previously described to protect against amylin cytotoxicity [36,37], 
were also tested for comparison. RIN-m5F cells were first treated for 48 h with inhibitors (see 
Materials and Methods) and cell viability was assessed by the XTT assay. Cell viability variation  
due to the compounds themselves was discarded since at the concentration used, none of the three 
newly discovered inhibitors, nor Congo red, reduced cell viability relative to the control. However, 
methylene blue did exert toxicity and it was not further tested. 
In our assay, cells treated with 75 µM human amylin (8–37) for 48 h showed (Figure 4) an 18% 
reduction in cell viability, compared to control cells (p = 0.0001). Neither benzbromarone nor folic 
acid could protect the cells from the cytotoxic effect exerted by amylin. However, quercetin increased 
the viability of amylin-challenged RIN-m5F cells from 81% to 89% (p = 0.028). While the statistical 
significance of this effect is clear, its magnitude is small. Accordingly, evaluation of the dose response 
quercetin protective effect will require the development of a more sensitive assay. On the other hand, 
and as expected from existing data, Congo red fully recovered the viability of amylin challenged  
RIN-m5F cells (p = 0.0076). 
Quercetin dihydrate:
3,31,41,5,7-pentahydroxyflavone dihydrate;
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate
Int. J. Mol. Sci. 2016, 17, 964 5 of 11 
and logP = −0.99). Folic acid contains one asymmetric center while benzbromarone and quercetin are 
not chiral. 
Table 1. Common names, systematic names, and chemical structures of three inhibitors of amylin  
(8–37) aggregation. 
Aggregation Inhibitors Structure 
Benzbromarone:  
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran;  
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone 
Quercetin dihydrate:  
3, ′,4′,5 7-pentahydroxyflavone dihydrate;  
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate 
Folic acid:  
pteroyl-L-glutamic acid 
pteroyl-L-glutamate 
The toxicity of the three inhibitors at different concentrations ranging from 10 nM to 200 µM was 
tested on HeLa cells using the Cell Proliferation Kit II (Roche, Basel, Switzerland), which detects cell 
dehydrogenase activity, by transformation of XTT (a tetrazolium salt) into a soluble colored formazan 
that can be quantified by absorbance. This absorbance is proportional to the number of viable cells. 
Toxicity curves (Figure S2) were fitted to a dose response equation to calculate half inhibitory 
concentrations (IC50). The most toxic inhibitor was benzbromarone, (IC50 = 43 ± 7 µM), then quercetin 
(110 ± 33 µM), although both of them were toxic only at relatively high concentrations. The toxicity 
of folic acid was very low (>200 µM) and could not be determined since it was above the tested range. 
These results showed that benzbromarone, quercetin, and folic acid display no significant toxicity 
towards HeLa cells at the medium-low concentration range tested. We then decided to keep a 
concentration of 10 µM for the three compounds during the following cytotoxicity protection 
experiments on cultured cells. 
2.4. Partial Inhibitory Effect of Quercetin on the Cytotoxicity Induced by Amylin (8–37) in Rat Insulinoma 
Pancreatic (RIN-m5F) Cells 
Rat insulinoma pancreatic cells (RIN-m5F) were used to evaluate whether any of the aggregation 
inhibitors could protect them against the cytotoxic effect exerted by amylin. The dyes Congo red and 
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Materials and Methods) and cell viability was assessed by the XTT assay. Cell viability variation  
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e toxicity of f lic acid was very low (>200 µM) a d could not be etermined since it was above
the tested range. These r sults showed that benzbr maron , quercetin, and folic aci display no
significan toxicity towards HeLa cells at the medium-low concentration ra e tested. We then d ided
to keep a concentration of 10 µM for the three compounds during the following cytotoxicity protection
experiments on cultured cells.
2.4. Partial Inhibitory Effect of Quercetin on the Cytotoxicity Induced by Amylin (8–37) in Rat Insulinoma
Pancreatic (RIN-m5F) Cells
Rat insulinoma pancreatic cells (RIN-m5F) were used to evaluate whether any of the aggregation
inhibitors could protect them against the cytotoxic effect exerted by amylin. The dyes Congo red and
methylene blue, which have been previously described to protect against amylin cytotoxicity [36,37],
were also tested for comparison. RIN-m5F cells were first treated for 48 h with inhibitors (see Materials
and Methods) and cell viability was assessed by the XTT assay. Cell viability variation due to the
compounds themselves was discarded since at the concentration used, none of the three newly
discovered inhibitors, nor Congo red, reduced cell viability relative to the control. However, methylene
blue did exert toxicity and it was not further tested.
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In our assay, cells treated with 75 µM human amylin (8–37) for 48 h showed (Figure 4) an 18%
reduction in cell viability, compared to control cells (p = 0.0001). Neither benzbromarone nor folic
acid could protect the cells from the cytotoxic effect exerted by amylin. However, quercetin increased
the viability of amylin-challenged RIN-m5F cells from 81% to 89% (p = 0.028). While the statistical
significance of this effect is clear, its magnitude is small. Accordingly, evaluation of the dose response
quercetin protective effect will require the development of a more sensitive assay. On the other hand,
and as expected from existing data, Congo red fully recovered the viability of amylin challenged
RIN-m5F cells (p = 0.0076).Int. J. Mol. Sci. 2016, 17, 964 6 of 11 
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s lf e l)- -tetr li -5-carboxanilide: X T assay. The results obtained were normalized
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2.5. Some Previous Evidences Relating Benzbromarone, Quercetin or Folic Acid with Type II Diabetes
The three inhibitory co pounds found benzbro arone, quercetin, and folic acid have been
idely studied in phar acological or clinical contexts. The observation that they inhibit a ylin
aggregation in vitro has pro pted us to exa ine hether they have been previously reported to
exert a beneficial influence in type II diabetes. Benzbro arone is a uricosuric agent used to treat
gout [38]. In a non-exhaustive literature search e have only found circu stantial evidence relating
benzbro arone ith glucose blood levels [39]. On the other hand, folic acid (vita in B9) is an
i portant biological cofactor necessary for DNA synthesis. Folic acid has been proposed to be beneficial
in type II diabetes due to its roles in accelerating the hydrolysis of fats, in lowering homocysteine
levels [40], or in improving the endothelial function [41]. Our results suggest a possible additional
role of folic acid, namely in reducing amylin aggregation, which might be worth testing. Quercetin
is a flavonoid found in many fruits, vegetables, and red wine. Interestingly, there is a wealth of
reports indicating that quercetin exhibits numerous beneficial effects in diabetes [42,43]. One such
effect appears to be that of regenerating pancreatic islets and preserving the integrity of pancreatic
β cells [44–47], and one mechanism invoked to explain this effect is that of reducing oxidative stress.
Quercetin has also been described to contribute to the control of blood glucose levels in vivo in animals
with streptozotocin-induced diabetes [44,45,48,49] and to improve hyperglycemia, dyslipidemia, and
antioxidant status in an animal model of type II diabetes mellitus: C57BL/KsJ-db/db mice [50]. Clinical
trials to test effects of quercetin on blood sugar and blood vessel function in type II diabetes have
been conducted [51]. In a recent study, morin, a flavonoid closely related to quercetin, has been
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described to inhibit the aggregation of amylin and even to disaggregate its fibers [52], while quercetin
has been reported not to inhibit amylin aggregation. Our results, however, clearly indicate that
quercetin inhibits amylin aggregation (Figures 1–3) and partly protects RIN-m5F cells from the damage
exerted by extracellularly added amylin. The different experimental conditions employed in both
studies might well account for this discrepancy; indeed, in the same study myricetin, a flavonoid
closely related to quercetin, was found to be inactive against amylin aggregation, whereas another
study has described its ability to interfere with amylin amyloid formation and cytoxicity [53]. In
addition, quercetin has been shown to inhibit the aggregation of a number of unrelated amyloidogenic
proteins linked to human disease, including the amyloid β peptide [54], lysozyme [55], insulin [56],
and α-synuclein [57,58]. In the light of this reported generic anti-amyloidogenic activity and the data
in the present study, we suggest that a more detailed examination of a potential beneficial effect of
quercetin in type II diabetes by reducing amylin aggregation in vivo and its concomitant oxidative
damage in β cells may be timely.
3. Materials and Methods
3.1. Materials
Human amylin (8–37) with a purity greater than 98% (as indicated by HPLC analysis) was
acquired from the American Peptide Company, Inc. (Sunnyvale, CA, USA). A 1 mg/mL peptide stock
solution was prepared by dissolving lyophilized peptide in 1,1,1,3,3,3-hexafluoro-2-propanol. The
solution was aliquoted and lyophilized. When required, aliquots were dissolved in 10 mM sodium
acetate (pH 5.5) to a final concentration of 500 µM, and centrifuged at 14,000 rpm in a microfuge for
30 min at 4 ˝C just before use. A library of 1120 approved drugs with purities greater than 90% was
purchased from Prestwick Chemical (Strasbourg, France). Thioflavin T (ThT) was purchased from the
American Peptide Company, Inc.
3.2. High Throughput Screening
ThT fluorescence increases upon binding to amyloid fibers [35]. A 650 µM ThT stock was prepared
in Phosphate-buffered saline: PBS buffer. A ThT binding-based initial screening of the commercially
available Prestwick library was performed using 96-well plates. Each well contained, in a total volume
of 200 µL, 10 mM sodium acetate (pH 5.5), 50 µM amylin (8–37), 6.5 µM ThT and five different
compounds (100 µM each). ThT emission fluorescence was continuously recorded with a FluoDia T
70 fluorimeter (PTI, Edison New Jersey, USA) using excitation and emission wavelengths of 450 and
500 nm, respectively. Amylin aggregation kinetics were followed at 37 ˝C for 4.5 h, with measurements
every 2.5 min and 3-s agitation before each measurement.
3.3. Turbidity Test
Turbidity tests were used to identify false positives of the high throughput screening [31]. For this
purpose, 50 µM amylin (8–37) was mixed in 10 mM sodium acetate (pH 5.5) with 100 µM compound
in a 1-cm quartz cuvette. Aggregation kinetics were monitored in a spectrophotometer recording
absorbance at 360 nm, every 30 min, for 5.5 h.
3.4. Transmission Electron Microscopy
Inhibitory compounds that passed the turbidity assay were further tested by transmission electron
microscopy (TEM). The size and morphology of the amyloid fibrils formed by amylin (8–37) in
the presence or absence of the different compounds were evaluated using a Hitachi H-7000-75 kV
microscope (Hitachi, Tokyo, Japan). For this we used a fresh mixture of 50 µM Amylin (8–37) and
100 µM compound in 10 mM sodium acetate buffer (pH 5.5) with 2.5% DMSO. The samples were
incubated at 37 ˝C for 24 h before a 5 µL drop of sample was placed on Formvar carbon support
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film on a copper grid. The samples were stained with 2% uranyl acetate for 1 min. Excess stain was
removed and the samples were allowed to dry at room temperature.
3.5. Cytotoxicity Assays of Aggregation Inhibitors in HeLa Cells
The cytotoxicity of the three inhibitory compounds found by ThT screening and confirmed
by turbidimetry and by TEM analysis was evaluated using HeLa cells growing in a RPMI-1640
medium with phenol red supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin sulfate,
and 10% fetal calf serum (all reagents from Invitrogen, Waltham, MA USA) at 37 ˝C in a 5% CO2
atmosphere. Cells were cultured in 25 cm2 polystyrene tissue culture flasks and sub-cultured
every three days. To evaluate the toxicity of the compounds, 100-µL aliquots of culture medium
containing 3 ˆ 104 cells were added to each well in the 96-well plates. After incubation for 24 h
in the absence or presence of compounds at different concentrations (between 10 nM and 200 µM),
cell viability was assessed using XTT: 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)
carbonyl]-2h-tetrazolium hydroxide following the manufacturer’s instructions (Cell Proliferation Kit
II, Roche). The culture medium was replaced with 100 µL of RPMI-1640 without phenol red plus 50 µL
of XTT reagent. The plates were incubated at 37 ˝C for 4 h and the optical density at 450 nm was
quantified using a spectrophotometric plate reader with the reference filter set to 620 nm. The values
obtained for controls corresponding to samples without compounds were considered to represent
100% viability. Half inhibitory concentrations (IC50) were calculated for each of the three compounds
evaluated by adjusting the viability obtained for the different concentrations of each compound, using
a dose-response function implemented in Origin Pro ® 8 (Northampton, MA, USA).
3.6. Cytotoxicity Assays of Amylin (8–37) in RIN-m5F Cells in Absence or Presence of Aggregation Inhibitors
Rat insulinoma cells RIN-m5F were purchased from ATCC (American Type Culture Collection).
The cytotoxic effect of human amylin (8–37) on RIN-m5F cells as well as the possible protective
effect exerted by the amylin aggregation inhibitors analyzed in vitro were determined using the
XTT reduction assay. Cells were cultured in 96-well plates at a density of 10,000 cells/well in fresh
RPMI-1640 medium for 24 h. Amylin (8–37), previously aliquoted from 1,1,1,3,3,3-hexafluoro-2-
propanol and lyophilized was reconstituted in 10 mM phosphate (pH 7.4), at a concentration of
500 µM. These fresh amylin solutions were then diluted to 75 µM in a culture medium in the presence
of a 10 µM inhibitor (which provides 1% DMSO to the mixture) or in presence of just 1% DMSO as
control (considered as 100% viability). After 48 h incubation, the culture medium was replaced with
100 µL of fresh RPMI-1640 medium, without phenol red, plus 50 µL of XTT reagent mixture following
the manufacturer recommendations (Roche). Plates were then incubated at 37 ˝C for 4 h in a humidified
atmosphere of 5% CO2 before measurement. Optical density was read at 450 nm with the reference
filter set to 620 nm, using a spectrophotometric plate reader (Synergy, HT, Bio Tek, Winooski, VT, USA).
Either triplicates or duplicates were used for each condition in seven independent experiments.
4. Conclusions
Using a combination of screening methods we have found that folic acid, quercetin, and
benzbromarone inhibit amylin aggregation in vitro. Besides, quercetin partly protects cultured
pancreatic insulinoma cells from the cytotoxic effect of amylin. A more detailed examination of
a potential beneficial effect of quercetin in type II diabetes by reducing amylin aggregation in vivo and
its concomitant oxidative damage in β cells may be timely.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/6/
964/s1.
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